Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPART trial of prophylactic oropharyngeal surfactant in extremely preterm infants
2016-004198-41Phase 3Completed
- Sponsor
- University College Dublin
- Start
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by University College Dublin. Primary endpoint: Endotracheal intubation for respiratory failure within 120 hours of birth. Started Nov 2016; status: completed.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2016-004198-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004198-41.